Testing two new drugs together for invasive bladder cancer

Plain-English translation of NCT06879145 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether SHR-A2102 combined with adebrelimab (an immunotherapy medication) can effectively treat muscular invasive bladder cancer. Researchers want to see if this medication combination works better than the standard treatments currently used. The study will enroll 840 patients and compare the new treatment to chemotherapy to understand which approach helps patients most.

Muscular invasive bladder cancer is a serious form of cancer that currently requires chemotherapy before surgery. This trial exists to find out whether this new medication combination might be more effective or better tolerated than the standard chemotherapy approach patients receive today.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have been diagnosed with muscular invasive bladder cancer that has not spread to other parts of your body
you are in good enough health to participate, with an expected lifespan of at least 2 years
you have not received cancer treatment in the 4 weeks before starting the study
your organs (kidneys, liver, heart, lungs) are functioning well enough to handle the medication

You likely don't qualify if…

you have received chemotherapy or other cancer treatment within the last 4 weeks
you have serious side effects from previous cancer treatments that haven't improved
you have a known or suspected autoimmune disease or immunodeficiency condition
you have uncontrolled heart disease or have had major surgery in the past 4 weeks
you have had a serious infection in the past 28 days

What participation looks like

You would receive the medication combination (SHR-A2102 and adebrelimab) either before surgery, after surgery, or both as part of your bladder cancer treatment. The study involves regular visits to the hospital or clinic to receive the medications, undergo imaging tests to monitor how the cancer responds, and have blood work done to check for side effects. You would be monitored carefully by the research team throughout the study to track how well the treatment is working and ensure you remain safe.

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality